Search the Newsreel

Gevo cancels plans for South Dakota SAF plant, focuses on North Dakota projects

Gevo has canceled its plans for a sustainable aviation fuel (SAF) production facility in Lake Preston, South Dakota, citing rising capital costs and construction expenses. The company will instead focus its efforts on developing two existing SAF projects in North Dakota. This strategic shift …

Evolent Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EVH) 2026-08-10

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …

Fund Update: 4,446,509 DEVON ENERGY (DVN) shares added to KING LUTHER CAPITAL MANAGEMENT CORP portfolio

KING LUTHER CAPITAL MANAGEMENT CORP has significantly increased its stake in DEVON ENERGY (DVN) by adding over 4.4 million shares to its portfolio, as reported in a new SEC 13F filing for the Q2 2026 period. This move is part of broader institutional activity …

Gevo Abandons ATJ-60 SAF Project, Pivots to North Dakota

Gevo Inc., an American renewable fuels producer, has canceled its ATJ-60 sustainable aviation fuel project in Lake Preston, South Dakota, citing an unfavorable regulatory environment regarding CO2 transport infrastructure. The project's viability was undermined by changes in state law and the South Dakota Public …

Evolution Metals Appoints Kenji Konishi as Head of Magnet Engineering Production

Evolution Metals & Technologies Corp. announced the appointment of Kenji Konishi as Head of Magnet Engineering Production, as disclosed in a Form 8-K filing on August 10, 2026. This appointment was also communicated via a press release issued on the same day.

Revolution Medicines, Inc. (RVMDW) Stock Price, News, Quote & History

Devon Energy Gains as Oil Strength and Earnings Positioning Lift Shares

BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia

BeOne Medicines and Revolution Medicines have formed a two-part partnership concerning RAS(ON) inhibitors in select Asian markets. The agreement includes clinical combination studies and regional commercialization rights for Revolution Medicines' four clinical-stage RAS(ON) inhibitors. BeOne will also fund and conduct a global registrational Phase …

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Evotec (NASDAQ:EVO) shares gapped up before the market opened, opening at $2.10 after closing at $2.00, and last traded at $2.0950 on modest volume. Analyst sentiment for the Germany-based biotechnology company is mixed, with a consensus "Hold" rating and a $3.00 average price target, …

Evommune (NYSE: EVMN) widens Q2 2026 loss but reports $288M cash runway

Evommune, Inc. (NYSE: EVMN) reported a widened net loss of $32.2 million for Q2 2026 and $53.9 million for the first six months of 2026. Despite the increased loss, the clinical-stage biotechnology company maintains a strong cash position of $288.0 million, providing a cash …

Form 8K Evolution Metals & Technologies For: 10 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by Evolution Metals & Technologies for August 10th. The content is brief, primarily serving as an alert for this financial filing, and includes market data and links to other financial news.

Evotec and Odyssey Therapeutics team up to accelerate AI-driven drug discovery for autoimmune diseases

Evotec SE and Odyssey Therapeutics have formed a strategic R&D collaboration to accelerate AI-driven drug discovery for autoimmune and inflammatory diseases. The partnership will combine Evotec’s data-driven drug discovery platform, AI-enabled technologies, and screening capabilities with Odyssey’s expertise in disease biology to identify and …

BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies

BeOne Medicines and Revolution Medicines have announced a collaboration to advance targeted therapies for RAS-addicted cancers. This partnership includes both clinical development of new treatment combinations and a regional commercialization agreement in Asia. The companies aim to explore combinations of BeOne's oncology candidates with …

Revolve Group's Active Customer Growth Signals Stronger Engagement

Revolve Group, Inc.'s RVLV growing active customer base continues to reinforce the strength of its brand and customer engagement strategy. In the second quarter of 2026, trailing 12-month active customers increased 11% year over year to 3.04 million, marking the company's highest customer growth …

Evolv Technologies (EVLV) reaches derivative case settlement with governance reforms and insurer-paid fees

Evolv Technologies Holdings, Inc. (EVLV) has reached a preliminary settlement in multiple stockholder derivative lawsuits, which includes a package of corporate governance reforms to be implemented and maintained for five years. The settlement, which covers federal and Delaware actions, does not require any direct …

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines and Revolution Medicines have announced a multi-part collaboration focusing on clinical development and regional commercialization. The collaboration includes evaluating drug combinations of BeOne's oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors for RAS-addicted cancers, and a regional rights agreement granting BeOne …

Evolution Metals & Technologies (Nasdaq:EMAT) - Stock Analysis

Evolution Metals & Technologies (EMAT) is a critical materials and technology company focused on rare earth magnets, with a current market cap of US$1.4 billion. The company faces significant financial risks including negative shareholder equity, past dilution, unprofitability, and limited financial data, despite a …

EOLS Q2 2026 Earnings: EPS of $0.02 Beats Estimates by 156.8% as Profitability Inflection Emerges - Special Dividend Alert

EMAT Q1 2026 Earnings: Deep EPS Miss of -$0.72 vs. Estimate Sends Shares Down 9.96% - Forward Guidance Trends

Embark Early Education Issues 10 Million New Shares to U.S. Institutional Investor

Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Why Is Revolve Group (RVLV) Drawing Fresh Attention Today?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Q2 earnings put Revolve Group in focus Revolve Group (RVLV) moved into the spotlight after releasing second quarter 2026 results, reporting higher sales and net …

Gevo FY2027 EPS Estimate Increased by Northland Securities

Northland Securities has increased its FY2027 EPS estimate for Gevo (NASDAQ: GEVO) to $0.08 from $0.06. This comes after Gevo's Q2 results modestly beat expectations, with $46.5 million in revenue and a $0.01 loss per share. Despite the positive adjustments, analysts maintain a consensus …

Trading Systems Reacting to (EOLS) Volatility

This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, …

Gevo, Inc. (NASDAQ:GEVO) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Gevo, Inc. (NASDAQ:GEVO) shareholders saw a 6.1% increase in shares after the company released its latest quarterly results, despite statutory losses growing significantly. Analysts have updated their forecasts, projecting revenues of US$191.2m in 2026 and a substantial reduction in loss per share to US$0.14, …

The Gevo, Inc. (NASDAQ:GEVO) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

This article analyzes Gevo, Inc.'s second-quarter results and the updated forecasts from analysts. It likely covers key financial metrics and how these have influenced expert opinions on the company's future performance and stock price targets.

Revolve Group Q2 Earnings Call Highlights

Revolve Group reported strong second-quarter 2026 results, with net sales up 12% to $347 million, driven by growth across all segments and markets, and significant new customer acquisition. The company highlighted increased profitability, strategic investments in brand building, AI, and physical retail expansion, and …

Devon Energy Corporation $DVN Shares Bought by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Devon Energy Corporation (DVN) by 60.6% in the second quarter, bringing its total holdings to 238,694 shares valued at $9.86 million. This comes as Devon Energy reported strong Q2 earnings, surpassing analyst estimates with $1.57 EPS on $7.42 …

Czech National Bank Has $13.56 Million Stake in Devon Energy Corporation $DVN

The Czech National Bank has significantly increased its stake in Devon Energy Corporation (NYSE: DVN) by 94.3% in Q2, now owning 328,174 shares valued at $13.56 million. This move comes as institutional investors and hedge funds collectively hold 69.72% of the company, following strong …

Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD

Assenagon Asset Management S.A. recently acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD), purchasing 200,486 shares valued at approximately $37.55 million in the second quarter. This move makes Assenagon Asset Management S.A. the owner of 0.09% of Revolution Medicines' stock. Other institutional investors …

Gevo, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GEVO) 2026-08-08

Gevo, Inc. (GEVO) published its Q2 2026 earnings call presentation on August 8, 2026. The company reported an EPS of -$0.01, which beat estimates by $0.00, and a revenue of $46.50M, a 7.11% year-over-year increase, beating expectations by $1.42M. The slide deck was released …

Evolent Health (NYSE:EVH) Announces Quarterly Earnings Results

Gevo (NASDAQ:GEVO) Releases Earnings Results, Beats Estimates By $0.01 EPS

Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next

Revolution Medicines (RVMD) reported a significant net loss in Q2 2026, yet its stock rose by 9.4% due to advancing daraxonrasib through FDA review for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have received daraxonrasib, indicating strong real-world interest, and …

Gevo, Inc. (GEVO) executive sells 10,257 shares to cover award withholding

Kimberly T. Bowron, Chief of Staff at Gevo, Inc. (GEVO), sold 10,257 shares of common stock on August 6, 2026, at an average price of $1.5458 per share. This sale was conducted under a Rule 10b5-1 trading plan to cover withholding obligations arising from …

Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside

Evommune, Inc.'s average 12-month price target has been reduced to $30.11 from $32.89 by 9 analysts, with individual forecasts ranging from $22 to $50 per share. This new target implies a potential upside of approximately 125% from its Aug. 6 closing price. The consensus …